Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC_EX:A61K39/395

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2025/140489MULTISPECIFIC ANTIBODIES AND USES THEREOF
WO 03.07.2025
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No PCT/CN2024/142997 Applicant VIBRANT PHARMA LIMITED Inventor WANG, Luquan
Provided are multispecific antibodies (e.g., bispecific antibodies or trispecific antibodies) or antigen-binding fragments thereof. In one aspect, the multispecific antibodies or antigen-binding fragments thereof can bind to a T cell antigen (e.g., CD3) and/or one or two tumor-associated antigens (e.g., CAIX, EGFR), or a combination thereof.
2.WO/2025/140654ANTI-CDH17 ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF AND USE THEREOF
WO 03.07.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2024/143461 Applicant GUANGDONG FAPON BIOPHARMA INC. Inventor ZHANG, Yibo
An anti-CDH17 antibody or an antigen-binding fragment thereof and the use thereof. The antibody can specifically bind to one or more extracellular domains in extracellular domains 1-7 of CDH17, has an ADCC activity, and can mediate cell endocytosis, thereby providing a new possibility for the treatment and/or prevention of cancers.
3.WO/2025/140324USE OF ANTI-PD-1 ANTIBODY COMBINED WITH CHEMOTHERAPEUTIC AGENT IN TREATMENT OF TUMORS
WO 03.07.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2024/142361 Applicant BIO-THERA SOLUTIONS, LTD. Inventor WANG, Hao
Provided is a use of an anti-PD-1 antibody combined with a chemotherapeutic agent in the treatment of tumors such as cervical cancer or endometrial cancer. In some embodiments, the chemotherapeutic agent comprises a taxane drug and/or a platinum drug. In some embodiments, the use further comprises a use of the anti-PD-1 antibody combined with bevacizumab.
4.WO/2025/144089MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO TL1A
WO 03.07.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/RU2024/050327 Applicant JOINT STOCK COMPANY "BIOCAD" Inventor NISKANEN, Sergei Andreevich
The present invention relates to the field of biotechnology and medicine, in particular to a monoclonal antibody or antigen-binding fragment thereof that specifically binds to TNF-like ligand 1A (TL1A). The invention further relates to nucleic acids encoding said antibody, expression vectors, host cells and methods for producing same, methods for producing the antibodies according to the invention, pharmaceutical compositions comprising the antibody or antigen-binding fragment thereof according to the invention, as well as to pharmaceutical compositions comprising the antibody or antigen-binding fragment thereof according to the invention and other therapeutically active compounds; to methods for treating TL1A-mediated diseases or disorders, to use of the antibody or antigen-binding fragment thereof or pharmaceutical composition thereof for treating TL1A-mediated diseases or disorders, and to use of the antibody or antigen-binding fragment thereof according to the invention and other therapeutically active compounds for treating TL1A-mediated diseases or disorders.
5.WO/2025/144474METHODS OF MANUFACTURING DIMERIC ANTIBODIES
WO 03.07.2025
Int.Class A61K 39/395
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Appl.No PCT/US2024/045707 Applicant MEDICOVESTOR, INC. Inventor LIM, Seah
This disclosure relates to dimeric immunotherapeutics that comprise two IgGs that are crosslinked with a disulfide bond. The two IgGs may be chimeras of two different heavy chains, in which one heavy chain includes a cysteine mutation that forms the disulfide bond, and the other heavy chain lacks the cysteine mutation. The presence of a cysteine mutation in only one of the heavy chains of an IgG avoids two disulfide bonds between the two IgGs, which increases the accessible orientations between the two crosslinked IgGs, and also avoids the formation of trimers and higher-order oligomers.
6.WO/2025/140634ANTI-CD276 NANOBODY, PREPARATION METHOD THEREFOR AND USE THEREOF
WO 03.07.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2024/143398 Applicant PERSONGEN BIOTHERAPEUTICS (SUZHOU) CO., LTD. Inventor YANG, Lin
Provided are an anti-CD276 nanobody, and a preparation method therefor and the use thereof. Specifically, further provided are a corresponding anti-CD276 antibody, a chimeric antigen receptor, a fusion protein, a recombinant protein, an antibody-drug conjugate, and an encoding nucleic acid, an expression vector, a host cell, etc. thereof. The anti-CD276 nanobody is high in affinity, simple in structure and easy to prepare, and the anti-CD276 nanobody-drug conjugate has a significant killing activity, thereby having application prospects in the fields such as tumor treatment and immunodetection.
7.WO/2025/145059CONSTRUCTS TARGETING MSLN ECD AND USES THEREOF
WO 03.07.2025
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/US2024/062123 Applicant EUREKA THERAPEUTICS, INC. Inventor ZHANG, Hongbing
The present application provides constructs comprising an antibody moiety that specifically binds to a mesothelin extracellular domain. Also provided are methods of making and using these constructs, and uses thereof, including treating and diagnosing diseases.
8.WO/2025/139525LY6G6D-TARGETED NANOBODY AND USE THEREOF
WO 03.07.2025
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2024/134172 Applicant SUNSHINE LAKE PHARMA CO., LTD. Inventor REN, Zhiheng
Provided are a Ly6G6D-targeted nanobody and a use thereof. Specifically, provided are an anti-Ly6G6D (lymphocyte antigen 6 complex, locus G6D) nanobody and an antigen-binding fragment. Also provided is a use of the nanobody or the antigen-binding fragment in the preparation of a drug for treating Ly6G6D-positive cancer.
9.WO/2025/138371PHB2 AS TUMOR IMMUNOTHERAPY TARGET AND USE THEREOF IN DRUG DEVELOPMENT
WO 03.07.2025
Int.Class C12Q 1/6886
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
68involving nucleic acids
6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
6883for diseases caused by alterations of genetic material
6886for cancer
Appl.No PCT/CN2024/073620 Applicant SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY Inventor PAN, Fan
Disclosed is the use of a PHB2 gene or a PHB2 protein as a new immune checkpoint. Targeting PHB2 can inhibit mitochondrial fusion, thereby increasing mitochondrial fragmentation, elevating mitochondrial metabolic levels, and enhancing the anti-tumor function of cells in vivo and in vitro. Moreover, targeting PHB2 can reduce the expression of PD-1, and when used in combination with a CTLA-4 monoclonal antibody, can enhance anti-tumor effects. On this basis, further disclosed is the use of a drug having an inhibitory effect on a PHB2 gene or a PHB2 protein in the preparation of a PD-1 inhibitor, or the use of same in combination with a PD-1 monoclonal antibody in the preparation of a therapeutic product or a preventive product for treating or preventing tumors. Further disclosed is the use of a drug having an inhibitory effect on a PHB2 gene or a PHB2 protein in combination with a CTLA-4 monoclonal antibody in the preparation of a therapeutic product or a preventive product for treating or preventing tumors. Further disclosed is the use of a drug having an inhibitory effect on a PHB2 gene or a PHB2 protein alone, in combination with a PD-1 monoclonal antibody or in combination with a CTLA-4 monoclonal antibody in immunotherapy, especially tumor immunotherapy. It has been found in experiments that tumors in PHB2+/- tumor-bearing mice are significantly reduced compared with those in the control. It has been further found that targeting mitochondrial PHB2 can increase mitochondrial fragmentation by means of inhibiting mitochondrial fusion, so that the mitochondrial metabolism is enhanced; moreover, after PHB2 knockout, PD-1 expression is reduced, and when used in combination with a CTLA-4 monoclonal antibody, can enhance anti-tumor effects.
10.WO/2025/139121CIRCULAR RNA ENCODING CARS AND THE USE THEREOF
WO 03.07.2025
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Appl.No PCT/CN2024/120871 Applicant THERORNA SHANGHAI CO., LTD. Inventor GAO, Lu
Provided is a circular RNA encoding CARs and the use thereof to create immune cells that target specific diseases, e. g., lymphoma, multiple myeloma and leukemia and auntoimmune diseases, such as systemic lupus erythematousus, lupus nephritis and myasthenia gravis.